Skip to main navigation

About

About Us

Management

Board of Directors

Contact Us

Our Pipeline

Our Pipeline

Our Product Candidates

- KER-050

- KER-047

- KER-012

Our Science

TGF-β Biology & Role in Diseases

Hematology Franchise

- KER-047 for Treatment of Functional Iron Deficiency

- KER-050 for Treatment of Ineffective Hematopoiesis

Pulmonary & Cardiovascular Franchise

- KER-012 for Treatment of Pulmonary and Cardiovascular Disorders

Investors and Media

Overview

Press Releases

Events & Presentations

Stock Information

Analyst Coverage

SEC Filings

Annual Reports

Corporate Governance

Investor FAQ

Investor Contact

Email Alerts

Careers

Working at Keros

Current Opportunities

Benefits

Folder: Our Pipeline

Folder: Our Science

Folder: Investors and Media

Folder: Careers

Board of Directors

Our Product Candidates

TGF-β Biology & Role in Diseases

Hematology Franchise

Pulmonary & Cardiovascular Franchise

- KER-047 for Treatment of Functional Iron Deficiency

- KER-050 for Treatment of Ineffective Hematopoiesis

- KER-012 for Treatment of Pulmonary and Cardiovascular Disorders

Events & Presentations

Stock Information

Analyst Coverage

Corporate Governance

Investor Contact

Working at Keros

Current Opportunities

Investor Contact

Investor Contact

Justin Frantz, Vice President
SOLEBURY TROUT
265 Franklin St. St 603
Boston, MA, 02110
jfrantz@soleburystrat.com
+1 (617)-221-9100

Name

Email

Subject

Comments

Leave this field blank

Follicular_Lymphoma_in_Bone_Marrow image

Keros Therapeutics

1050 Waltham Street, Suite 302
Lexington, MA 02421
+1 (617) 314-6297

Expanded Access Policy